{"id":2136,"date":"2026-09-10T16:49:26","date_gmt":"2026-09-10T08:49:26","guid":{"rendered":"https:\/\/www.millibuff.com\/?p=2136"},"modified":"2026-09-10T16:50:37","modified_gmt":"2026-09-10T08:50:37","slug":"%e5%b0%8f%e7%89%9b%e6%b4%9e%e5%af%9f-%e5%ad%90%e5%ae%ab%e5%86%85%e8%86%9c%e7%99%8c%e7%a7%91%e6%99%ae%ef%bd%9c%e7%bb%9d%e7%bb%8f%e5%90%8e%e9%98%b4%e9%81%93%e5%87%ba%e8%a1%80%e5%8b%bf%e8%bd%bb","status":"publish","type":"post","link":"https:\/\/www.millibuff.com\/?p=2136","title":{"rendered":"\u5c0f\u725b\u6d1e\u5bdf | \u5b50\u5bab\u5185\u819c\u764c\u79d1\u666e\uff5c\u7edd\u7ecf\u540e\u9634\u9053\u51fa\u8840\u52ff\u8f7b\u89c6\uff0c\u4e00\u6587\u770b\u61c2\u8bca\u65ad\u4e0e\u5168\u6d41\u7a0b\u6cbb\u7597"},"content":{"rendered":"\n
\u514d\u8d23\u58f0\u660e<\/strong>\uff1a\u672c\u6587\u4ec5\u4e3a\u533b\u5b66\u79d1\u666e\uff0c\u4e0d\u66ff\u4ee3\u4e34\u5e8a\u533b\u5e08\u4e2a\u4f53\u5316\u8bca\u7597\u610f\u89c1\uff0c\u5177\u4f53\u8bca\u7597\u8bf7\u9075\u533b\u5631\u3002<\/h6>\n\n\n\n

\u4e00\u3001\u6d41\u884c\u75c5\u5b66\uff1a\u53d1\u75c5\u7387\u6500\u5347\u7684”\u5bcc\u764c”<\/strong><\/h4>\n\n\n\n
\"\"<\/figure>\n\n\n\n

\u56fd\u5bb6\u764c\u75c7\u4e2d\u5fc3\u6570\u636e\u663e\u793a\uff0c2022 \u5e74\u6211\u56fd\u5b50\u5bab\u5185\u819c\u764c\u65b0\u53d1\u7ea6 7.77 \u4e07\u4f8b\u3001\u6b7b\u4ea1\u7ea6 1.35 \u4e07\u4f8b\uff0c\u53d1\u75c5\u7387\u9010\u5e74\u4e0a\u5347[1]<\/sup>\u3002\u8fd9\u4e0e\u80a5\u80d6\u7387\u5347\u9ad8\u3001\u4eba\u53e3\u8001\u9f84\u5316\u5bc6\u5207\u76f8\u5173\u2014\u2014\u80a5\u80d6\u53ef\u4f7f\u53d1\u75c5\u98ce\u9669\u589e\u52a0 2~3 \u500d<\/strong>\uff0c\u662f\u6700\u91cd\u8981\u7684\u53ef\u5e72\u9884\u5371\u9669\u56e0\u7d20\u3002<\/p>\n\n\n\n

\u5b50\u5bab\u5185\u819c\u764c\u9ad8\u53d1\u4e8e\u56f4\u7edd\u7ecf\u671f\u548c\u7edd\u7ecf\u540e\u5973\u6027\uff0c50~54 \u5c81\u4e3a\u53d1\u75c5\u9ad8\u5cf0<\/strong>\uff0c\u7ea6 75% \u7684\u60a3\u8005\u53d1\u75c5\u5e74\u9f84\u5728 50 \u5c81\u4ee5\u4e0a\u3002\u8fd1\u5e74\u6765 40 \u5c81\u4ee5\u4e0b\u60a3\u8005\u6bd4\u4f8b\u867d\u4ec5\u5360 5%~10%\uff0c\u4f46\u5448\u4e0a\u5347\u8d8b\u52bf[1-2]<\/sup>\u3002<\/p>\n\n\n\n

\u9ad8\u5371\u56e0\u7d20\u5305\u62ec\uff1a\u2460\u4ee3\u8c22\u4e09\u8054\u5f81\uff08\u80a5\u80d6\u3001\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u538b\uff09\uff1b\u2461\u65e0\u5b55\u6fc0\u7d20\u5bf9\u6297\u7684\u96cc\u6fc0\u7d20\u957f\u671f\u66b4\u9732\uff08\u521d\u6f6e\u65e9\u3001\u7edd\u7ecf\u665a\u3001\u591a\u56ca\u5375\u5de2\u7efc\u5408\u5f81\u3001\u957f\u671f\u4f7f\u7528\u4ed6\u83ab\u6614\u82ac\u7b49\uff09\uff1b\u2462\u9057\u4f20\u56e0\u7d20\u2014\u2014Lynch \u7efc\u5408\u5f81\u60a3\u8005\u53d1\u75c5\u98ce\u9669\u663e\u8457\u5347\u9ad8[2]<\/sup>\u3002<\/p>\n\n\n\n

\u75c5\u7406\u4e0a\u5206\u4e24\u578b\uff1a\u2160\u578b<\/strong>\uff08\u5b50\u5bab\u5185\u819c\u6837\u764c\uff0c\u96cc\u6fc0\u7d20\u4f9d\u8d56\u578b\uff0c\u5360 70%~80%[19]<\/sup>\uff0c\u9884\u540e\u8f83\u597d\uff09\uff1b\u2161\u578b<\/strong>\uff08\u6d46\u6db2\u6027\u764c\u3001\u900f\u660e\u7ec6\u80de\u764c\u3001\u764c\u8089\u7624\u7b49\uff0c\u5360 20%~30%[19]<\/sup>\uff0c\u6076\u6027\u7a0b\u5ea6\u9ad8\u3001\u6613\u590d\u53d1\uff09\u3002<\/p>\n\n\n\n

\u4e8c\u3001\u8bca\u65ad\uff1a”\u75c7\u72b6-\u5f71\u50cf-\u75c5\u7406”\u4e09\u7ed3\u5408<\/strong><\/h4>\n\n\n\n

\u4efb\u4f55\u7edd\u7ecf\u540e\u51fa\u8840\u6216\u5f02\u5e38\u51fa\u8840\u7684\u5973\u6027\uff0c\u90fd\u5efa\u8bae\u6309\u4ee5\u4e0b\u6d41\u7a0b\u7cfb\u7edf\u6392\u67e5\uff1a<\/p>\n\n\n\n

\u2460 \u7ecf\u9634\u9053\u8d85\u58f0\uff08\u4e00\u7ebf\u7b5b\u67e5\uff09<\/strong>\uff1a\u8bc4\u4f30\u5185\u819c\u539a\u5ea6\uff0c\u7edd\u7ecf\u540e\u5185\u819c\u589e\u539a \u2265 4~5 mm \u9700\u8b66\u60d5[2]<\/sup>\u3002\u8d85\u58f0\u5f02\u5e38\u8005\u5fc5\u987b\u884c\u75c5\u7406\u68c0\u67e5\u786e\u8ba4\uff0c\u4e0d\u80fd\u4ec5\u51ed\u8d85\u58f0\u6392\u9664\u6216\u786e\u8bca<\/strong>\u3002<\/p>\n\n\n\n

\u2461 \u76c6\u8154\u589e\u5f3a MRI<\/strong>\uff1a\u7cbe\u51c6\u8bc4\u4f30\u808c\u5c42\u6d78\u6da6\u6df1\u5ea6\u3001\u5bab\u9888\u95f4\u8d28\u53d7\u7d2f\u53ca\u6dcb\u5df4\u7ed3\u60c5\u51b5\uff0c\u662f\u624b\u672f\u51b3\u7b56\u7684\u91cd\u8981\u4f9d\u636e\u3002<\/p>\n\n\n\n

\u2462 \u5bab\u8154\u955c\u4e0b\u6d3b\u68c0\/\u8bca\u65ad\u6027\u522e\u5bab\uff08\u786e\u8bca\u91d1\u6807\u51c6\uff09<\/strong>\uff1a\u5bab\u8154\u955c\u5b9a\u4f4d\u6d3b\u68c0\u8bca\u65ad\u51c6\u786e\u7387\u8fbe 94%\uff0c\u663e\u8457\u4f18\u4e8e\u8d85\u58f0\uff0880%\uff09\u548c MRI\uff0884%\uff09[21]<\/sup>\u3002<\/p>\n\n\n\n

\u2463 \u5206\u5b50\u5206\u578b\u68c0\u6d4b\uff08\u6307\u5357\u63a8\u8350\u5e38\u89c4\u5f00\u5c55\uff09<\/strong>\uff1a\u786e\u8bca\u540e\u5e94\u884c\u5206\u5b50\u5206\u578b\u68c0\u6d4b\uff0c\u5206\u4e3a\u56db\u578b[2]<\/sup>[19]<\/sup>[20]<\/sup>\uff1a<\/p>\n\n\n\n

    \n
  • POLE \u8d85\u7a81\u53d8\u578b<\/strong>\uff08~7%\uff09\uff1a\u9884\u540e\u6700\u597d\uff0c\u6cbb\u7597\u5b9c”\u505a\u51cf\u6cd5”<\/li>\n\n\n\n
  • dMMR\/MSI-H \u578b<\/strong>\uff08~28%\uff09\uff1aDNA \u9519\u914d\u4fee\u590d\u7f3a\u9677\uff0c\u5bf9\u514d\u75ab\u6cbb\u7597\u9ad8\u5ea6\u654f\u611f<\/li>\n\n\n\n
  • p53 \u5f02\u5e38\u578b<\/strong>\uff08~26%\uff09\uff1a\u9884\u540e\u5dee\uff0c\u9700\u66f4\u79ef\u6781\u7684\u5168\u8eab\u6cbb\u7597<\/li>\n\n\n\n
  • NSMP \u578b<\/strong>\uff08~39%\uff09\uff1a\u65e0\u7279\u6b8a\u5206\u5b50\u7279\u5f81\uff0c\u4f46\u5f02\u8d28\u6027\u663e\u8457\uff0cER\u3001L1CAM \u7b49\u6807\u5fd7\u7269\u53ef\u8fdb\u4e00\u6b65\u98ce\u9669\u5206\u5c42[23]<\/sup><\/li>\n<\/ul>\n\n\n\n

    2023 \u5e74 FIGO \u5206\u671f\u5df2\u5c06\u5206\u5b50\u5206\u578b\u6574\u5408\u5165\u4e34\u5e8a\u5206\u671f\u4f53\u7cfb[17][22]<\/sup>\uff0c\u5206\u5b50\u5206\u578b\u5df2\u6210\u4e3a\u6cbb\u7597\u51b3\u7b56\u7684\u65b0\u6838\u5fc3<\/strong>\u3002<\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n

    \u88681\uff1a2023 \u5e74 FIGO \u5206\u671f\uff08<\/em>\u6765\u6e90\uff1a\u9038\u4ed9\u5987\u7624\u516c\u4f17\u53f7\uff09<\/em><\/p>\n\n\n\n

    \u2464 \u5168\u8eab\u5f71\u50cf\u8bc4\u4f30<\/strong>\uff1a\u5bf9\u6709\u8fdc\u5904\u8f6c\u79fb\u98ce\u9669\u8005\u884c\u80f8\u90e8 CT\u3001PET\/CT \u7b49\u8bc4\u4f30\u3002<\/p>\n\n\n\n

    \u4e09\u3001\u6cbb\u7597\uff1a\u624b\u672f\u4e3a\u4e3b\uff0c\u5206\u5b50\u5206\u578b\u6307\u5bfc\u7cbe\u51c6\u5316<\/strong><\/h4>\n\n\n\n

    \u6574\u4f53\u539f\u5219<\/strong>\uff1a\u65e9\u671f\u4ee5\u624b\u672f \u00b1 \u8f85\u52a9\u6cbb\u7597\u4e3a\u4e3b\uff0c\u591a\u6570\u53ef\u6cbb\u6108\uff1b\u665a\u671f\u53ca\u590d\u53d1\u4ee5\u5168\u8eab\u7cfb\u7edf\u6cbb\u7597\u4e3a\u4e3b\u3002\u6cbb\u7597\u7b56\u7565\u5728\u5206\u5b50\u5206\u578b\u6307\u5bfc\u4e0b”\u505a\u52a0\u6cd5\u6216\u505a\u51cf\u6cd5”\u3002<\/p>\n\n\n\n

    \u6cbb\u7597\u8fdb\u884c\u5371\u9669\u7a0b\u5ea6\u5206\u5c42\uff0c\u4ee5\u51b3\u5b9a\u624b\u672f\u8303\u56f4\u3001\u662f\u5426\u4fdd\u7559\u751f\u80b2\u529f\u80fd\u53ca\u540e\u7eed\u8f85\u52a9\u6cbb\u7597\u65b9\u6848\u3002<\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n

    \u88682\uff1a\u5b50\u5bab\u5185\u819c\u764c\u5371\u9669\u7a0b\u5ea6\u5206\u5c42\u8868[20]<\/sup><\/p>\n\n\n\n

    1. \u624b\u672f\u6cbb\u7597<\/strong><\/p>\n\n\n\n

    \u6807\u51c6\u5206\u671f\u624b\u672f\u4e3a\u5168\u5b50\u5bab\u5207\u9664 + \u53cc\u9644\u4ef6\u5207\u9664 + \u6dcb\u5df4\u7ed3\u8bc4\u4f30<\/strong>\u3002\u524d\u54e8\u6dcb\u5df4\u7ed3\u6d3b\u68c0\uff08SLN\uff09\u521b\u4f24\u66f4\u5c0f\u3001\u53ef\u964d\u4f4e\u672f\u540e\u6dcb\u5df4\u6c34\u80bf\u7b49\u5e76\u53d1\u75c7\uff0c\u5df2\u5199\u5165\u4e13\u5bb6\u5171\u8bc6[2][20]<\/sup>\u3002<\/p>\n\n\n\n

    \u4fdd\u7559\u751f\u80b2\u529f\u80fd<\/strong>\uff08\u4e25\u683c\u7b5b\u9009\uff1aG1 \u5b50\u5bab\u5185\u819c\u6837\u817a\u764c\u3001\u5c40\u9650\u5185\u819c\u3001ER\/PR \u9633\u6027\uff09\uff1a\u91c7\u7528\u5927\u5242\u91cf\u5b55\u6fc0\u7d20 \u00b1 GnRH-a[2-3]<\/sup>\u3002\u5206\u5b50\u5206\u578b\u5bf9\u4fdd\u80b2\u7597\u6548\u6709\u91cd\u8981\u6307\u5bfc\u610f\u4e49<\/strong>\u2014\u2014NSMP \u578b\u6709\u6548\u7387\u53ef\u8fbe 82%\uff0c\u662f\u6700\u4f73\u83b7\u76ca\u4eba\u7fa4\uff1bMMR-d \u578b 6 \u4e2a\u6708\u5b8c\u5168\u7f13\u89e3\u7387\u4ec5 11.1%\uff0c\u9700\u8c28\u614e\u5e76\u6392\u67e5 Lynch \u7efc\u5408\u5f81\uff1bp53 \u5f02\u5e38\u578b\uff08\u5c24\u5176\u662f\u9ad8\u5371\/\u665a\u671f\u60a3\u8005\uff09\u5219\u4e0d\u63a8\u8350\u4fdd\u80b2\u6cbb\u7597[20-21]<\/sup>\u3002\u6cbb\u7597\u671f\u95f4\u6bcf 3~6 \u4e2a\u6708\u5bab\u8154\u955c\u8bc4\u4f30\uff0c6~12 \u4e2a\u6708\u65e0\u6548\u9700\u8f6c\u6839\u6cbb\u624b\u672f[21]<\/sup>\u3002<\/p>\n\n\n\n

    2. \u672f\u540e\u8f85\u52a9\u6cbb\u7597<\/strong><\/p>\n\n\n\n

    \u6839\u636e\u5206\u671f\u3001\u7ec4\u7ec7\u5b66\u7c7b\u578b\u3001\u5206\u5b50\u5206\u578b\u51b3\u5b9a\uff1a<\/p>\n\n\n\n

      \n
    • \u653e\u7597<\/strong>\uff1a\u9634\u9053\u8fd1\u8ddd\u79bb\u653e\u7597\u964d\u4f4e\u6b8b\u7aef\u590d\u53d1\uff1b\u76c6\u8154\u5916\u7167\u5c04\u7528\u4e8e\u6dcb\u5df4\u7ed3\u8f6c\u79fb\u6216\u9ad8\u5371\u60a3\u8005<\/li>\n\n\n\n
    • \u5316\u7597<\/strong>\uff1a\u5361\u94c2 + \u7d2b\u6749\u9187\uff08TC\uff09\u65b9\u6848\uff0c\u7528\u4e8e\u2162\u671f\u53ca\u4ee5\u4e0a\u6216\u7279\u6b8a\u7ec4\u7ec7\u5b66\u7c7b\u578b<\/li>\n\n\n\n
    • \u514d\u75ab\u6cbb\u7597\uff08CSCO \u2160\u7ea7\u63a8\u8350\uff09<\/strong>\uff1a\u5e15\u535a\u5229\u73e0\u5355\u6297 + TC \u7528\u4e8e\u2162-\u2163\u671f\u672f\u540e\u8f85\u52a9\u3002KEYNOTE-B21 \u7814\u7a76\u5168\u4eba\u7fa4\u672a\u663e\u8457\u83b7\u76ca\uff082 \u5e74 DFS 75% vs 76%\uff09\uff0c\u4f46 dMMR \u4e9a\u7ec4 2 \u5e74 DFS \u8fbe 92% vs 80%\uff08HR 0.31\uff09<\/strong>\uff0c\u8f85\u52a9\u514d\u75ab\u5bf9 dMMR \u4eba\u7fa4\u83b7\u76ca\u660e\u786e[4]<\/sup><\/li>\n<\/ul>\n\n\n\n

      3. \u665a\u671f\/\u590d\u53d1\u4e00\u7ebf\u6cbb\u7597<\/strong><\/p>\n\n\n\n

        \n
      1. <\/li>\n<\/ol>\n\n\n\n

        \u590d\u53d1\u548c\u8f6c\u79fb\u6027\u5b50\u5bab\u5185\u819c\u764c\u4e00\u7ebf\u6cbb\u7597<\/strong>\u65b9\u6848<\/strong>[<\/sup>2<\/sup>]<\/sup>\uff08<\/em>\u6765\u6e90\uff1a2025\u5e74CSCO\u5b50\u5bab\u5185\u819c\u764c\u8bca\u7597\u6307\u5357<\/em>\uff09<\/em><\/p>\n\n\n\n

        \"\"<\/figure>\n\n\n\n

        “\u5316\u7597 + \u514d\u75ab”\u5df2\u6210\u4e3a dMMR\/MSI-H \u4eba\u7fa4\u7684\u4e00\u7ebf\u65b0\u6807\u51c6<\/strong>\uff0c\u56db\u9879\u2162\u671f\u7814\u7a76\u4e00\u81f4\u8bc1\u5b9e\u83b7\u76ca\uff1a<\/p>\n\n\n\n

        \u7814\u7a76<\/strong><\/td>\u65b9\u6848<\/strong><\/td>dMMR PFS HR<\/strong><\/td>pMMR PFS HR<\/strong><\/td><\/tr>
        NRG-GY018<\/strong>[6]<\/strong><\/sup><\/td>\u5e15\u535a\u5229\u73e0\u5355\u6297 + \u5316\u7597<\/td>0.30<\/td>0.54<\/td><\/tr>
        RUBY<\/strong>[7]<\/strong><\/sup><\/td>\u591a\u5854\u5229\u5355\u6297 + \u5316\u7597<\/td>0.28<\/td>0.76<\/td><\/tr>
        AtTEnd<\/strong>[8]<\/strong><\/sup><\/td>\u963f\u66ff\u5229\u73e0\u5355\u6297 + \u5316\u7597<\/td>0.36<\/td>0.92<\/td><\/tr>
        DUO-E<\/strong>[9]<\/strong><\/sup><\/td>\u5ea6\u4f10\u5229\u5c24\u5355\u6297 + \u5316\u7597<\/td>0.42<\/td>0.77<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        HR\uff08\u98ce\u9669\u6bd4\uff09\u8d8a\u5c0f\u83b7\u76ca\u8d8a\u5927\uff1bdMMR = \u9519\u914d\u4fee\u590d\u7f3a\u9677\uff0cpMMR = \u9519\u914d\u4fee\u590d\u529f\u80fd\u6b63\u5e38\u3002<\/p>\n\n\n\n

        2026 \u5e74\u56fd\u5185\u5df2\u6709 2 \u6b3e\u514d\u75ab\u836f\u7269\u83b7\u6279<\/strong>\u7528\u4e8e dMMR \u665a\u671f\/\u590d\u53d1\u4e00\u7ebf\uff1a\u5ea6\u4f10\u5229\u5c24\u5355\u6297\uff081 \u6708\uff09\u548c\u5e15\u535a\u5229\u73e0\u5355\u6297\uff082 \u6708\uff09[5]<\/sup>\u3002\u591a\u5854\u5229\u5355\u6297\u867d\u7597\u6548\u663e\u8457\uff08dMMR \u4eba\u7fa4\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e 72%[7]<\/sup>\uff09\uff0c\u4f46\u5c1a\u672a\u5728\u4e2d\u56fd\u5185\u5730\u83b7\u6279\u3002<\/p>\n\n\n\n

        pMMR \u4eba\u7fa4\u540c\u6837\u53ef\u4ece\u514d\u75ab + \u5316\u7597\u4e2d\u83b7\u76ca\uff0c\u4f46\u5e45\u5ea6\u56e0\u7814\u7a76\u800c\u5f02\uff08HR 0.54~0.92\uff09\u3002HER2 \u9633\u6027\u7684\u5b50\u5bab\u6d46\u6db2\u6027\u764c\/\u764c\u8089\u7624\u53ef\u8003\u8651\u5361\u94c2 + \u7d2b\u6749\u9187 + \u66f2\u59a5\u73e0\u5355\u6297\uff08CSCO \u2161\u7ea7\u63a8\u8350\uff09\uff0c\u5efa\u8bae\u5e38\u89c4\u8fdb\u884c HER2 \u68c0\u6d4b[2][20]<\/sup>\u3002<\/p>\n\n\n\n

        4. \u590d\u53d1\u4e8c\u7ebf\u53ca\u540e\u7ebf\u6cbb\u7597<\/strong><\/p>\n\n\n\n

          \n
        1. <\/li>\n<\/ol>\n\n\n\n

          \u590d\u53d1\u548c\u8f6c\u79fb\u6027\u5b50\u5bab\u5185\u819c\u764c\u7cfb\u7edf\u6027\u6cbb\u7597\u65b9\u6848<\/strong>[<\/sup>2<\/sup>]<\/sup>\uff08<\/em>\u6765\u6e90\uff1a2025\u5e74CSCO\u5b50\u5bab\u5185\u819c\u764c\u8bca\u7597\u6307\u5357<\/em>\uff09<\/em><\/p>\n\n\n\n

          \"\"<\/figure>\n\n\n\n

          \u4ee5\u4e0b\u65b9\u6848\u5747\u9002\u7528\u4e8e\u65e2\u5f80\u542b\u94c2\u5316\u7597\u5931\u8d25\u540e<\/strong>\u7684\u4e8c\u7ebf\u53ca\u540e\u7ebf\u3002<\/p>\n\n\n\n

            \n
          • \u9776\u514d\u8054\u5408\uff1a<\/strong><\/li>\n\n\n\n
          • \u4ed1\u4f10\u66ff\u5c3c + \u5e15\u535a\u5229\u73e0\u5355\u6297<\/strong>\uff08KEYNOTE-775\uff09\uff1a\u5168\u4eba\u7fa4 mPFS 7.2 vs 3.8 \u4e2a\u6708\uff0c\u662f pMMR \u590d\u53d1\u60a3\u8005\u7684\u6807\u51c6\u9009\u62e9[10]<\/sup><\/li>\n\n\n\n
          • \u8d1d\u83ab\u82cf\u62dc\u5355\u6297 + \u5b89\u7f57\u66ff\u5c3c<\/strong>\uff08ETER200 \u2161\u671f\uff09\uff1aORR 34.1%\u3001\u4e2d\u4f4d OS 21.8 \u4e2a\u6708\uff0c2024 \u5e74 11 \u6708\u83b7\u6279[11]<\/sup><\/li>\n\n\n\n
          • \u4fe1\u8fea\u5229\u5355\u6297 + \u544b\u55b9\u66ff\u5c3c<\/strong>\uff08FRUSICA-1 \u2161\u671f\uff09\uff1aORR 35.6%\u3001mPFS 9.5 \u4e2a\u6708\u3001\u4e2d\u4f4d OS 21.3 \u4e2a\u6708\uff0c2024 \u5e74 12 \u6708\u83b7\u6279[12]<\/sup><\/li>\n\n\n\n
          • \u514d\u75ab\u5355\u836f\uff08\u540e\u7ebf\u7ecf\u6cbb\uff09\uff1a<\/strong><\/li>\n\n\n\n
          • dMMR\/MSI-H \u60a3\u8005\u53ef\u83b7\u76ca\u663e\u8457\u2014\u2014\u591a\u5854\u5229\u5355\u6297 GARNET \u7814\u7a76\uff08\u6ce8\uff1a\u540e\u7ebf\u7ecf\u6cbb\u6570\u636e\uff0c\u4e0d\u53ef\u7528\u4e8e\u521d\u6cbb\u4e00\u7ebf\uff096 \u5e74\u968f\u8bbf ORR 45.5%\u30016 \u5e74 OS \u7387 50.1%[13]<\/sup><\/li>\n\n\n\n
          • ADC \u65b0\u836f\uff08\u540e\u7ebf\u63a2\u7d22\uff09\uff1a<\/strong><\/li>\n\n\n\n
          • HER2 \u9776\u5411\u5fb7\u66f2\u59a5\u73e0\u5355\u6297<\/strong>\uff08DESTINY-PanTumor02\uff1a\u5b50\u5bab\u5185\u819c\u764c\u961f\u5217 ORR 57.5%[14]<\/sup>\uff09\u2014\u2014\u6ce8\uff1a\u56fd\u5185\u6682\u672a\u83b7\u6279\u5b50\u5bab\u5185\u819c\u764c\u9002\u5e94\u75c7\uff0c\u4ec5\u4e3a\u4e34\u5e8a\u7814\u7a76\u6570\u636e<\/strong><\/li>\n\n\n\n
          • TROP2 \u9776\u5411\u82a6\u5eb7\u6c99\u59a5\u73e0\u5355\u6297\u3001FR\u03b1 \u9776\u5411 ADC \u8054\u5408\u514d\u75ab\uff08BAT8006+BAT1308 \u2160b\/\u2161\u671f\uff0cORR 38.2%[16]<\/sup>\uff09\u7b49\u4e5f\u5728\u79ef\u6781\u63a8\u8fdb<\/li>\n<\/ul>\n\n\n\n

            \u590d\u53d1\u96be\u6cbb\u60a3\u8005\u6cbb\u7597\u9009\u62e9\u4ecd\u7136\u6709\u9650\uff0c\u53c2\u52a0\u4e34\u5e8a\u8bd5\u9a8c\u662f\u83b7\u5f97\u524d\u6cbf\u65b0\u7597\u6cd5\u7684\u91cd\u8981\u9014\u5f84<\/strong>\uff0c\u4f46\u9700\u6ce8\u610f\u4e34\u5e8a\u8bd5\u9a8c\u5b58\u5728\u672a\u77e5\u98ce\u9669\uff0c\u987b\u5728\u533b\u751f\u5145\u5206\u8bc4\u4f30\u540e\u81ea\u613f\u53c2\u4e0e\u3002<\/p>\n\n\n\n

            \u56db\u3001\u5b50\u5bab\u5185\u819c\u764c\u524d\u6cbf\u6cbb\u7597\u8fdb\u5c55<\/strong><\/h4>\n\n\n\n

            2026 \u5e74 ASCO \u5e74\u4f1a\u53ca SGO \u5e74\u4f1a\u96c6\u4e2d\u53d1\u5e03\u4e86\u591a\u9879\u5b50\u5bab\u5185\u819c\u764c\u91cd\u78c5\u7814\u7a76\uff0c\u6db5\u76d6\u514d\u75ab\u4e00\u7ebf\u957f\u671f\u968f\u8bbf\u3001\u65b0\u578b ADC\u3001\u53cc\u7279\u5f02\u6027\u6297\u4f53\u3001CDK4\/6 \u6291\u5236\u5242\u53ca ctDNA \u751f\u7269\u6807\u5fd7\u7269\u7b49\u65b9\u5411\u3002\u4ee5\u4e0b\u6c47\u603b 7 \u9879\u5173\u952e\u7814\u7a76\uff1a<\/p>\n\n\n\n

            \"\"<\/figure>\n\n\n\n
              \n
            • dMMR \u4eba\u7fa4”\u4e34\u5e8a\u6cbb\u6108”\u8d8b\u52bf\u660e\u786e<\/strong>\uff1aRUBY 4\u5e74OS\u738772.8%\uff0cNRG-GY018 48\u4e2a\u6708OS\u738780%\uff0c\u5373\u4f7f\u5bf9\u7167\u7ec4\u4ea4\u53c9\u4f7f\u7528\u514d\u75ab\u540e\u83b7\u76ca\u4ecd\u6301\u7eed\u2014\u2014dMMR \u4e00\u7ebf\u514d\u75ab\u8054\u5408\u5316\u7597\u5df2\u6210\u4e3a”\u6cbb\u7597\u5bfc\u5411”\u6807\u51c6\u3002<\/li>\n\n\n\n
            • pMMR \u4eba\u7fa4\u8fce\u6765\u7a81\u7834<\/strong>\uff1aPD-1\/VEGF\u53cc\u6297SSGJ-707\u5728\u4f20\u7edf\u514d\u75ab\u83b7\u76ca\u6709\u9650\u7684pMMR\u4eba\u7fa4\u4e2d\u786e\u8ba4ORR\u8fbe81.8%\u3001DCR 100%\uff0c\u6709\u671b\u6539\u53d8pMMR\u6cbb\u7597\u683c\u5c40\u3002<\/li>\n\n\n\n
            • ADC\u586b\u8865\u7a7a\u767d<\/strong>\uff1aB7-H4 ADC\u653b\u514b\u514d\u75ab\u8010\u836f\uff08ORR 48%\uff09\u3001HER2 ADC\u60e0\u53ca\u66f4\u5e7fIHC\u8868\u8fbe\u8c31\uff08IHC 1+~3+\u5747\u6709\u7f13\u89e3\uff09\u3002<\/li>\n<\/ul>\n\n\n\n

              \u4e94\u3001\u603b\u7ed3<\/h4>\n\n\n\n

              \u5b50\u5bab\u5185\u819c\u764c\u662f\u9884\u540e\u6700\u597d\u7684\u5987\u79d1\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u65e9\u671f\u89c4\u8303\u6cbb\u7597\u540e 5 \u5e74\u751f\u5b58\u7387\u53ef\u8fbe 95% \u5de6\u53f3<\/strong>[2][18]<\/sup>\u3002\u7cbe\u51c6\u624b\u672f\u3001\u5206\u5b50\u5206\u578b\u6307\u5bfc\u4e0b\u7684\u514d\u75ab\u4e0e\u9776\u5411\u6cbb\u7597\uff0c\u5df2\u8ba9\u8d8a\u6765\u8d8a\u591a\u665a\u671f\u60a3\u8005\u83b7\u5f97\u957f\u671f\u751f\u5b58\u3002<\/p>\n\n\n\n

              \u6bd4\u60a3\u75c5\u540e\u6c42\u533b\u66f4\u91cd\u8981\u7684\u662f\u65e9\u8bc6\u522b\u5f02\u5e38\u4fe1\u53f7<\/strong>\uff1a\u7edd\u7ecf\u540e\u51fa\u8840\u3001\u7ecf\u671f\u5f02\u5e38\u3001\u5f02\u5e38\u6392\u6db2\u5207\u52ff\u7b80\u5355\u5f52\u4e3a”\u66f4\u5e74\u671f”\u3002\u8d85\u58f0\u53d1\u73b0\u5185\u819c\u589e\u539a\uff0c\u52a1\u5fc5\u5b8c\u6210\u75c5\u7406\u786e\u8ba4\u3002\u786e\u8bca\u540e\u9075\u4ece\u6307\u5357\u89c4\u8303\u6cbb\u7597\uff0c\u5b9a\u671f\u968f\u8bbf\uff1b\u540c\u65f6\u63a7\u5236\u4f53\u91cd\u3001\u7ba1\u7406\u8840\u7cd6\u8840\u538b\uff0c\u4ece\u6e90\u5934\u964d\u4f4e\u98ce\u9669\u3002<\/p>\n\n\n\n

              \u53c2\u8003\u8d44\u6599\u8bf4\u660e<\/strong><\/p>\n\n\n\n

              [1]<\/strong> \u90d1\u8363\u5bff, \u9648\u8339, \u97e9\u51b0\u5cf0, \u7b49. 2022\u5e74\u4e2d\u56fd\u6076\u6027\u80bf\u7624\u6d41\u884c\u60c5\u51b5\u5206\u6790[J]. \u4e2d\u534e\u80bf\u7624\u6742\u5fd7, 2024, 46(6): 493-502. \uff08Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.\uff09<\/p>\n\n\n\n

              [2]<\/strong> \u4e2d\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a(CSCO)\u6307\u5357\u5de5\u4f5c\u59d4\u5458\u4f1a. CSCO\u5b50\u5bab\u5185\u819c\u764c\u8bca\u7597\u6307\u5357(2025\u7248)[M]. \u5317\u4eac: \u4eba\u6c11\u536b\u751f\u51fa\u7248\u793e, 2025.<\/p>\n\n\n\n

              [3]<\/strong> \u4e2d\u534e\u533b\u5b66\u4f1a\u5987\u79d1\u80bf\u7624\u5b66\u5206\u4f1a, \u4e2d\u56fd\u7814\u7a76\u578b\u533b\u9662\u5b66\u4f1a\u5987\u4ea7\u79d1\u5b66\u4e13\u4e1a\u59d4\u5458\u4f1a, \u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u5987\u4ea7\u79d1\u533b\u5e08\u5206\u4f1a\u5987\u79d1\u80bf\u7624\u5b66\u7ec4. \u5b50\u5bab\u5185\u819c\u764c\u4fdd\u7559\u751f\u80b2\u529f\u80fd\u591a\u5b66\u79d1\u8bca\u7597\u4e34\u5e8a\u8def\u5f84(2024\u5e74\u7248)[J]. \u4e2d\u56fd\u5b9e\u7528\u5987\u79d1\u4e0e\u4ea7\u79d1\u6742\u5fd7, 2024, 40(11): 1114-1120. DOI: 10.19538\/j.fk2024110113.<\/p>\n\n\n\n

              [4]<\/strong> Van Gorp T, Cibula D, Lv W, et al. Pembrolizumab or placebo with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer: the ENGOT-en11\/GOG-3053\/KEYNOTE-B21 randomised, double-blind, phase III trial[J]. Ann Oncol, 2024, 35(11): 968-980. DOI: 10.1016\/j.annonc.2024.08.2242.<\/p>\n\n\n\n

               [5]<\/strong> \u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(NMPA). \u836f\u54c1\u83b7\u6279\u4e0a\u5e02\u516c\u793a: \u5ea6\u4f10\u5229\u5c24\u5355\u6297\u8054\u5408\u5361\u94c2\u548c\u7d2b\u6749\u9187\u7528\u4e8e dMMR \u539f\u53d1\u665a\u671f\u6216\u590d\u53d1\u6027\u5b50\u5bab\u5185\u819c\u764c\u4e00\u7ebf\u6cbb\u7597(2026-01-22); \u5e15\u535a\u5229\u73e0\u5355\u6297\u8054\u5408\u5361\u94c2\u548c\u7d2b\u6749\u9187\u7528\u4e8e dMMR \u539f\u53d1\u665a\u671f\u6216\u590d\u53d1\u6027\u5b50\u5bab\u5185\u819c\u764c\u4e00\u7ebf\u6cbb\u7597(2026-02-06)[EB\/OL]. [2026-08-14]. https:\/\/www.nmpa.gov.cn\/.<\/p>\n\n\n\n

               [6]<\/strong> Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2159-2170. DOI: 10.1056\/NEJMoa2302312. (NRG-GY018)<\/p>\n\n\n\n

              [7]<\/strong> Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2145-2158. DOI: 10.1056\/NEJMoa2216334. (RUBY)<\/p>\n\n\n\n

              [8]<\/strong> Colombo N, Biagioli E, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2024, 25(9): 1135-1146. DOI: 10.1016\/S1470-2045(24)00334-6.<\/p>\n\n\n\n

              [9]<\/strong> Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the Phase III DUO-E trial[J]. J Clin Oncol, 2024, 42(3): 283-299. DOI: 10.1200\/JCO.23.02132.<\/p>\n\n\n\n

              [10]<\/strong> Makker V, Colombo N, Casado Herr\u00e1ez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer[J]. N Engl J Med, 2022, 386(5): 437-448. DOI: 10.1056\/NEJMoa2108330. (KEYNOTE-775)<\/p>\n\n\n\n

               [11]<\/strong> \u6b63\u5927\u5929\u6674\u836f\u4e1a\u96c6\u56e2. \u8d1d\u83ab\u82cf\u62dc\u5355\u6297\u8054\u5408\u5b89\u7f57\u66ff\u5c3c\u6cbb\u7597\u590d\u53d1\u6027\u6216\u8f6c\u79fb\u6027\u5b50\u5bab\u5185\u819c\u764c: ETER200 \u7814\u7a76(2024 IGCS \u5e74\u4f1a\u62a5\u544a)\u53ca NMPA \u83b7\u6279\u516c\u544a[EB\/OL]. (2024-11-27). [2026-08-14]. https:\/\/www.cttq.com\/.<\/p>\n\n\n\n

              [12]<\/strong> \u4fe1\u8fbe\u751f\u7269. \u4fe1\u8fea\u5229\u5355\u6297\u8054\u5408\u544b\u55b9\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u5b50\u5bab\u5185\u819c\u764c: FRUSICA-1 \u7814\u7a76(2024 ASCO \u5e74\u4f1a\u62a5\u544a)\u53ca NMPA \u83b7\u6279\u516c\u544a[EB\/OL]. (2024-12-03). [2026-08-14]. https:\/\/www.innoventbio.com\/.<\/p>\n\n\n\n

               [13]<\/strong> 2026 ESMO \u5987\u79d1\u764c\u75c7\u5927\u4f1a. GARNET \u7814\u7a76 6 \u5e74\u968f\u8bbf: \u591a\u5854\u5229\u5355\u6297\u5355\u836f\u6cbb\u7597 dMMR\/MSI-H \u665a\u671f\u6216\u590d\u53d1\u6027\u5b50\u5bab\u5185\u819c\u764c[Abstract 69O]. 2026.<\/p>\n\n\n\n

              [14]<\/strong> Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINY-PanTumor02[J]. J Clin Oncol, 2024, 42(1): 47-58. DOI: 10.1200\/JCO.23.02005.<\/p>\n\n\n\n

               [15]<\/strong> 2026 ASCO \u5e74\u4f1a. DESTINY-PanTumor03 \u4e2d\u56fd\u6865\u63a5\u7814\u7a76 Part 1: \u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u6cbb\u7597 HER2 IHC 3+ \u5b9e\u4f53\u7624[Abstract 3026]. 2026.<\/p>\n\n\n\n

               [16]<\/strong> 2026 ASCO \u5e74\u4f1a. BAT8006(FR\u03b1 ADC)\u8054\u5408 BAT1308(PD-1)\u6cbb\u7597\u665a\u671f\u5b50\u5bab\u5185\u819c\u764c[Abstract 5512; CTR20242449]. 2026.<\/p>\n\n\n\n

              [17]<\/strong> Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023 revision[J]. Int J Gynecol Obstet, 2023, 162: 383-394. DOI: 10.1002\/ijgo.14923.<\/p>\n\n\n\n

               [18]<\/strong> National Cancer Institute. SEER Cancer Stat Facts: Endometrial Cancer[DB\/OL]. Bethesda: NCI. [2026-08-14]. https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html.<\/p>\n\n\n\n

              [19]<\/strong> \u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3. \u6cbb\u7597\u5b50\u5bab\u5185\u819c\u764c\u65b0\u836f\u4e34\u5e8a\u7814\u53d1\u6280\u672f\u6307\u5bfc\u539f\u5219(\u8bd5\u884c)[S\/OL]. \u5317\u4eac: \u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3, 2025-01. [2026-08-14]. https:\/\/www.cde.org.cn\/.<\/p>\n\n\n\n

               [20]<\/strong> \u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u5987\u4ea7\u79d1\u533b\u5e08\u5206\u4f1a\u5987\u79d1\u80bf\u7624\u5b66\u7ec4, \u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u5fae\u65e0\u521b\u533b\u5b66\u4e13\u4e1a\u59d4\u5458\u4f1a. \u5b50\u5bab\u5185\u819c\u764c\u591a\u5b66\u79d1\u56e2\u961f\u534f\u4f5c\u8bca\u7597\u4e34\u5e8a\u5b9e\u8df5\u4e2d\u56fd\u4e13\u5bb6\u5171\u8bc6[J]. \u4e2d\u534e\u5987\u4ea7\u79d1\u6742\u5fd7, 2024, 59(1): 22-40. DOI: 10.3760\/cma.j.cn112141-20231014-00147.<\/p>\n\n\n\n

              [21]<\/strong> \u4e2d\u534e\u533b\u5b66\u4f1a\u5987\u4ea7\u79d1\u5b66\u5206\u4f1a\u5987\u79d1\u5185\u955c\u5b66\u7ec4, \u4e2d\u56fd\u6c11\u65cf\u536b\u751f\u534f\u4f1a\u5973\u6027\u5065\u5eb7\u4e0e\u751f\u6b96\u75be\u75c5\u7ba1\u7406\u5206\u4f1a, \u5317\u4eac\u533b\u5b66\u4f1a\u5987\u79d1\u5185\u955c\u5b66\u5206\u4f1a. \u5bab\u8154\u955c\u5b50\u5bab\u5185\u819c\u764c\u5f62\u6001\u7279\u5f81\u5728\u4fdd\u7559\u751f\u80b2\u529f\u80fd\u6cbb\u7597\u4e2d\u4f5c\u7528\u7684\u4e2d\u56fd\u4e13\u5bb6\u5171\u8bc6[J]. \u4e2d\u534e\u5987\u4ea7\u79d1\u6742\u5fd7, 2025, 60(2): 83-93. DOI: 10.3760\/cma.j.cn112141-20250106-00012.<\/p>\n\n\n\n

              [22]<\/strong> \u5b8b\u8273, \u5218\u7231\u519b. \u5b50\u5bab\u5185\u819c\u764cFIGO 2023\u5206\u671f\u7684\u66f4\u65b0\u53ca\u5176\u4e34\u5e8a\u75c5\u7406\u610f\u4e49[J]. \u4e2d\u534e\u5987\u4ea7\u79d1\u6742\u5fd7, 2024, 59(3): 179-183. DOI: 10.3760\/cma.j.cn112141-20231127-00228.<\/p>\n\n\n\n

              [23]<\/strong> \u9b4f\u94f1\u6960, \u848b\u82b3, \u5411\u9633. NSMP\u578b\u5b50\u5bab\u5185\u819c\u764c\u8bca\u7597\u7684\u7814\u7a76\u8fdb\u5c55[J]. \u4e2d\u534e\u5987\u4ea7\u79d1\u6742\u5fd7, 2026, 61(4): 340-347.<\/p>\n\n\n\n

              <\/p>\n\n\n\n

              <\/p>\n\n\n\n

              \u64b0\u6587\uff1a\u674e\u6653\u5b87<\/p>\n\n\n\n

              \u5ba1\u6838\uff1a\u5bab\u96ea<\/p>\n","protected":false},"excerpt":{"rendered":"

              \u7edd\u7ecf\u540e\u9634\u9053\u51fa\u8840\uff0c\u662f\u5b50\u5bab\u5185\u819c\u764c\u6700\u5178\u578b\u7684\u65e9\u671f\u4fe1\u53f7\u3002\u7ea6 90% \u7684\u60a3\u8005\u4ee5\u6b64\u4e3a\u9996\u53d1\u75c7\u72b6[2]\uff0c\u5374\u5e38\u88ab\u8bef\u8ba4\u4e3a”\u66f4\u5e74\u671f\u7d0a\u4e71”\u800c\u5ef6\u8bef\u5c31\u8bca\u3002
              \n\u672c\u6587\u4f9d\u636e\u300aCSCO \u5b50\u5bab\u5185\u819c\u764c\u8bca\u7597\u6307\u5357\uff082025\u7248\uff09\u300b\u3001NMPA \u6700\u65b0\u83b7\u6279\u4fe1\u606f\u53ca\u591a\u9879\u2162\u671f\u4e34\u5e8a\u7814\u7a76\u6570\u636e\uff0c\u68b3\u7406\u5b50\u5bab\u5185\u819c\u764c\u7684\u8bca\u7597\u5168\u6d41\u7a0b\u3002<\/p>\n","protected":false},"author":1,"featured_media":2137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[147],"tags":[35,15,32,34],"class_list":["post-2136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-147","tag-35","tag-15","tag-32","tag-34"],"_links":{"self":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2136"}],"version-history":[{"count":3,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2136\/revisions"}],"predecessor-version":[{"id":2146,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2136\/revisions\/2146"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/media\/2137"}],"wp:attachment":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}